NO20061678L - NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav - Google Patents

NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav

Info

Publication number
NO20061678L
NO20061678L NO20061678A NO20061678A NO20061678L NO 20061678 L NO20061678 L NO 20061678L NO 20061678 A NO20061678 A NO 20061678A NO 20061678 A NO20061678 A NO 20061678A NO 20061678 L NO20061678 L NO 20061678L
Authority
NO
Norway
Prior art keywords
binding molecule
human
phytosocial
nogo
applications
Prior art date
Application number
NO20061678A
Other languages
English (en)
Norwegian (no)
Inventor
Martin E Schwab
Carmen Barske
Anis Khusro Mir
Alessandra Vitaliti
Stefan Frentzel
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of NO20061678L publication Critical patent/NO20061678L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20061678A 2003-09-19 2006-04-12 NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav NO20061678L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321997.9A GB0321997D0 (en) 2003-09-19 2003-09-19 Organic compound
PCT/EP2004/010489 WO2005028508A2 (en) 2003-09-19 2004-09-17 Nogo-a binding with enhanced affinity and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NO20061678L true NO20061678L (no) 2006-06-16

Family

ID=29266310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061678A NO20061678L (no) 2003-09-19 2006-04-12 NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav

Country Status (25)

Country Link
US (2) US20090181023A1 (pt)
EP (3) EP2423225A3 (pt)
JP (1) JP2007527232A (pt)
KR (1) KR20060119982A (pt)
CN (1) CN1878792A (pt)
AR (1) AR045671A1 (pt)
AU (2) AU2004274164B2 (pt)
BR (1) BRPI0414174B8 (pt)
CA (1) CA2538725C (pt)
CO (1) CO5680457A2 (pt)
EC (1) ECSP066431A (pt)
GB (1) GB0321997D0 (pt)
IL (2) IL174145A (pt)
IS (1) IS8404A (pt)
MA (1) MA28088A1 (pt)
MY (2) MY161068A (pt)
NO (1) NO20061678L (pt)
NZ (1) NZ545679A (pt)
PE (1) PE20050949A1 (pt)
RU (1) RU2380377C2 (pt)
SG (1) SG146660A1 (pt)
TN (1) TNSN06085A1 (pt)
TW (1) TWI372060B (pt)
WO (1) WO2005028508A2 (pt)
ZA (1) ZA200601842B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548013A (en) 2003-12-22 2009-04-30 Glaxo Group Ltd Immunoglobulins
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
CA2614076A1 (en) * 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2704357C (en) * 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (pt) 2012-07-05 2015-05-08 Glaxo Group Ltd
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体
CN114470197B (zh) * 2022-02-16 2023-10-03 天津长和生物技术有限公司 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2046632C (en) 1989-02-13 1999-05-11 Schering Aktiengesellschaft Thrombolytic from vampire bat saliva
JP2002522016A (ja) * 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
EP2990394A1 (en) * 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
NZ548013A (en) * 2003-12-22 2009-04-30 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
WO2005028508A3 (en) 2005-07-07
TW200517123A (en) 2005-06-01
EP2248827A1 (en) 2010-11-10
ECSP066431A (es) 2006-09-18
IL174145A (en) 2010-11-30
RU2380377C2 (ru) 2010-01-27
BRPI0414174B1 (pt) 2019-06-04
TWI372060B (en) 2012-09-11
IL174145A0 (en) 2006-08-01
EP1668033A2 (en) 2006-06-14
JP2007527232A (ja) 2007-09-27
IS8404A (is) 2006-04-10
AR045671A1 (es) 2005-11-02
MY158078A (en) 2016-08-30
AU2004274164A1 (en) 2005-03-31
US20090181023A1 (en) 2009-07-16
US20110008334A1 (en) 2011-01-13
GB0321997D0 (en) 2003-10-22
CO5680457A2 (es) 2006-09-29
BRPI0414174B8 (pt) 2021-05-25
RU2006112849A (ru) 2007-12-20
CA2538725A1 (en) 2005-03-31
CA2538725C (en) 2010-12-21
EP2423225A2 (en) 2012-02-29
KR20060119982A (ko) 2006-11-24
AU2004274164B2 (en) 2009-02-05
CN1878792A (zh) 2006-12-13
NZ545679A (en) 2009-11-27
IL203007A0 (en) 2011-08-01
EP2423225A3 (en) 2013-03-20
ZA200601842B (en) 2007-09-26
MA28088A1 (fr) 2006-08-01
TNSN06085A1 (en) 2007-10-03
SG146660A1 (en) 2008-10-30
AU2009200237A1 (en) 2009-02-12
AU2009200237B2 (en) 2011-05-19
MY161068A (en) 2017-04-14
PE20050949A1 (es) 2005-12-16
IL203007A (en) 2013-10-31
BRPI0414174A (pt) 2006-10-31
WO2005028508A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
Khavinson et al. Peptide regulation of gene expression: a systematic review
NO20092331L (no) LINGO-bindingsmolekyler og farmasoytisk anvendelse derav
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
Delbecq et al. A mechanism of subunit recruitment in human small heat shock protein oligomers
ATE446313T1 (de) Muteine von tränen-lipocalin
EE05075B1 (et) POL1212 aminohappej„rjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappej„rjestust omava valgu valmistamiseks
ATE440825T1 (de) Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CO6470863A2 (es) Mutantes fgf21 y usos de los mismos
NO20055919L (no) 3-Subtituerte,5,6-Diaryl-Pyrazin-2-Karboksamid og 2-Sulfonamidderivater som CB1-Modulatorar
TW200517123A (en) Nogo-A binding molecules and pharmaceutical use thereof
MY149546A (en) Improved nogo-a binding molecules and pharmaceutical use tereof
SE0301987D0 (sv) New polypeptide
Zehner et al. Two-site internally cooperative mechanism for enzyme kinetics in a hydrogel forming recombinant protein
BR0315845A (pt) Compostos de pirazina como moduladores de crf
Mythili et al. A novel method of isolation of a bone‐morphogenetic‐protein‐like protein from ossein
WO2005005668A3 (en) Diagnosis and treatment methods related to aging (8a)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application